Equities research analysts predict that Prothena Co. PLC (NASDAQ:PRTA) will report ($0.54) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Prothena’s earnings. Prothena reported earnings of ($0.70) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 22.9%. The firm is scheduled to announce its next earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Prothena will report full-year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.27) to ($2.05). For the next financial year, analysts expect that the firm will report earnings of ($1.49) per share, with EPS estimates ranging from ($2.01) to ($1.00). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Prothena.
Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. The company had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.22 million. Prothena had a negative net margin of 10,435.79% and a negative return on equity of 27.59%.
Several research analysts have recently weighed in on the stock. BidaskClub cut shares of Prothena from a “sell” rating to a “strong sell” rating in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Thursday, May 16th. ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Wednesday, June 19th. Finally, Barclays restated a “sell” rating and set a $9.00 target price on shares of Prothena in a report on Friday, May 31st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $11.26.
A number of institutional investors and hedge funds have recently made changes to their positions in PRTA. Bank of Montreal Can acquired a new position in Prothena during the second quarter worth $36,000. Meeder Asset Management Inc. acquired a new position in Prothena during the second quarter worth $37,000. Quantamental Technologies LLC boosted its holdings in Prothena by 142.9% during the first quarter. Quantamental Technologies LLC now owns 4,129 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,429 shares during the last quarter. Prudential Financial Inc. acquired a new position in Prothena during the second quarter worth $109,000. Finally, SG Americas Securities LLC acquired a new position in Prothena during the first quarter worth $114,000. Institutional investors and hedge funds own 99.69% of the company’s stock.
Shares of Prothena stock traded up $0.16 on Wednesday, hitting $7.91. The company had a trading volume of 6,426 shares, compared to its average volume of 161,023. The firm has a market capitalization of $303.21 million, a P/E ratio of -2.20 and a beta of 2.26. Prothena has a twelve month low of $7.52 and a twelve month high of $15.91. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.94 and a quick ratio of 14.95. The stock has a 50-day moving average of $9.57 and a 200-day moving average of $10.90.
Prothena Company Profile
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.